^
    Back
    Association details:
    Biomarker:NPM1-ALK I1171T
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    J Cancer Res Clin Oncol
    Title:

    Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma

    Excerpt:
    The resistant cecDNA sequencing of ALK kinase domain revealed activating mutations—I1171T in Karpas299CR and F1174C in Karpas299CHR. The resistant cells displayed diminished sensitivity to structurally unrelated ALK inhibitors—crizotinib, CH5424802 and TAE684.lated ALK inhibitors—crizotinib, CH5424802 and TAE684.
    DOI:
    10.1007/s00432-014-1589-3